PBLS Overview

Parabilis Medicines Inc, formerly known as Fog Pharmaceuticals Inc, is a United States-based company. The Company operates as a clinical-stage biopharmaceutical company. It is focused on discovering and developing transformative medicines that target disease-driving proteins historically considered “undruggable.” It leverages its Helicon platform, which consists of engineered, stabilized, cell‑penetrant helical peptides designed to bind and modulate intracellular protein targets with high specificity and affinity. Its pipeline primarily focuses on oncology, with programs such as zolucatetide being evaluated in clinical trials for solid tumors.

Wall Street analysts forecast PBLS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBLS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Parabilis Medicines Inc revenue for the last quarter amounts to NaN USD, decreased

Parabilis Medicines Inc. EPS for the last quarter amounts to USD, decreased

Parabilis Medicines Inc (PBLS) has 0 emplpoyees as of June 20 2026.

Today PBLS has the market capitalization of 3.07B USD.